<a href="https://laohu8.com/S/CTOR">Citius Oncology</a> Announces Warrant and Share Issuance in $18 Million Offering
Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。